SHANGHAI SHEN LIAN BIOMEDICAL CORPORATION

Shanghai Shen Lian Biomedical Corporation

688098

CNE100003P17

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
5.49 ^CNY	-0.36%		-1.79%	-26.60%

05-06	Shen Lian Biomedical Gets Certificate for Swine Fever Vaccine; Shares Up 3%	MT
04-26	Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Shanghai Shen Lian Biomedical Corporation Declares a Cash Dividend for 2019, Payable on June 8, 2020

June 31, 2020

Shanghai Shen Lian Biomedical Corporation announced the implements the scheme of rights and interests distribution for 2019 declared a cash dividend of RMB 0.08 (taxes included) per A share. Record date is June 5, 2020 Ex-dividend date is June 8, 2020. Cash dividend payable date is June 8, 2020.

Latest news about Shanghai Shen Lian Biomedical Corporation

Shen Lian Biomedical Gets Certificate for Swine Fever Vaccine; Shares Up 3%	05-06	MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Shen Lian Biomedical Gets Nod for Two Pig Virus Detection Kits	04-26	MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Shen Lian Biomedical Obtains Production License, GMP Certificate	11-21	MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Shen Lian Biomedical Forms Tie-up to Develop African Swine Fever Vaccine	16/10/23	MT
Certain A Shares of Shanghai Shen Lian Biomedical Corporation are subject to a Lock-Up Agreement Ending on 16-OCT-2023.	15/10/23	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Shen Lian Biomedical Passes Regulatory Inspection	15/08/23	MT
Shen Lian Biomedical's Bovine Vaccine Passes Regulatory Evaluation	19/05/23	MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Shanghai Shen Lian Biomedical Ties Up with Caremed Biomedical to Set Up Joint Venture	19/04/23	MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Shen Lian Biomedical Gets Marketing Approval for Pig Vaccine in China	10/11/22	MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022	25/10/22	CI
Certain A Shares of Shanghai Shen Lian Biomedical Corporation are subject to a Lock-Up Agreement Ending on 16-OCT-2022.	15/10/22	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	27/04/22	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	27/04/22	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2021	28/10/21	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	20/08/21	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	25/04/21	CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	25/04/21	CI
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease	29/03/21	CI

Chart Shanghai Shen Lian Biomedical Corporation

Duration

Period

Chart Shanghai Shen Lian Biomedical Corporation

More charts

Company Profile

Shanghai Shen Lian Biomedical Corp is a China-based company mainly engaged in the research, development, production and sales of veterinary biological products. The Company is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The Company's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The Company mainly sells its products within domestic market.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
SHANGHAI SHEN LIAN BIOMEDICAL CORPORATION	-26.60%	311M
ZOETIS INC.	-12.83%	78.51B
BLUESTAR ADISSEO COMPANY	+25.12%	3.71B
VIRBAC	+0.28%	3.27B
JINYU BIO-TECHNOLOGY CO., LTD.	-1.21%	1.64B
VIMIAN GROUP AB	+15.88%	1.64B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-18.97%	1.36B
VETOQUINOL SA	+1.95%	1.34B
WUHAN KEQIAN BIOLOGY CO.,LTD	-6.82%	1.22B
PULIKE BIOLOGICAL ENGINEERING, INC.	+4.02%	1.12B

Veterinary Drugs